Brian Finrow

Brian Finrow is a former Cooley securities lawyer and co-founder/CEO of Lumen Bioscience, a clinical-stage biotechnology company in Seattle.

Articles by Brian Finrow

You Can Just (Not) Do Stuff: FDA’s Power to De-Bottleneck Early-Stage Clinical Trials

ByBrian Finrow

February 17th 2026

Without new legislation, pilot programs, or years of rulemaking, the agency could use enforcement discretion to create a fast, risk-based pathway for low-risk early-stage trials.

Brian Finrow

Articles by Brian Finrow

You Can Just (Not) Do Stuff: FDA’s Power to De-Bottleneck Early-Stage Clinical Trials

Latest Updated Articles

Trending on PharmExec

How to Bring a Breakthrough Rare Disease Product to Patients in Record Time: Q&A with Brian Laird

FDA Issues CRL to Disc Medicine for Eythropoietic Protoporphyria Treatment Bitopertin

Edwards Life Sciences Lifts Anti-Copycat Policy

Eli Lilly Generates $1.5 Billion Stockpile of Orforglipron Ahead of FDA Decision

Pharmaceutical Executive Daily: Disc Medicine Receives CRL from FDA for Bitopertin